# Efficacy and Safety of Saccharomyces Boulardii in the Treatment of Small Intestinal Bacterial Overgrowth

> **NCT04627337** · PHASE4 · COMPLETED · sponsor: **Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno** · enrollment: 71 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Saccharomyces Boulardii 250 MG
- **BEHAVIORAL:** Dietary advice following a low fermentation diet

## Key facts

- **NCT ID:** NCT04627337
- **Lead sponsor:** Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-01
- **Primary completion:** 2018-07-30
- **Final completion:** 2018-08-31
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2020-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04627337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04627337, "Efficacy and Safety of Saccharomyces Boulardii in the Treatment of Small Intestinal Bacterial Overgrowth". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04627337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*